A male patient underwent an aquablation procedure for symptomatic benign prostatic hyperplasia (bph).Procept biorobotics corporation (procept) was made aware that prior to the second treatment pass, the patient experienced a suspected air embolism (per manufacturer's instructions for use, embolism is a perioperative risk of the aquablation procedure).It was reported that the patient is stable.No malfunction of the aquabeam robotic system was reported.
|
The device was not returned for investigation because it is a reusable component, which is still being used at the user facility.The investigation of this event consisted of a review of the treatment log files, device history record (dhr) and labeling.A review of the device history record (dhr) ab2000-b / serial number (b)(6) was conducted, which confirmed that there were no non-conformances, failures, discrepancies, or missed steps during the manufacturing process that could be related to the reported event.The review indicated that the system met all design and manufacturing specifications when released for distribution.The aquabeam robotic system instructions for use (ifu), ifu0101-00, rev.E, was reviewed and states the following: 4.3.Warnings: procedure: as with any surgical urologic procedure, potential perioperative risks of the aquablation procedure include: o embolism.A root cause for the reported event could not be determined.The aquabeam robotic system instructions for use list embolism as a potential risk of the aquablation procedure.Based on the review of the information provided, plus a review of the treatment log files, dhr, and ifu, this event is considered not to be device-related.Submission of this report does not constitute an admission that the manufacturer's product caused or contributed to the event.
|